Simon Rule
西蒙·鲁尔
MD, FRCP, FRCPath
Professor of Hematology and Consultant Hematologist血液学教授兼顾问血液科医生
👥Biography 个人简介
Professor Simon Rule is the United Kingdom's leading authority on mantle cell lymphoma and a globally recognized expert in BTK inhibitor therapy for B-cell malignancies. He was the principal investigator of the ACE-LY-004 trial establishing acalabrutinib monotherapy in relapsed/refractory MCL and has been a key contributor to the clinical development of pirtobrutinib — the first non-covalent BTK inhibitor approved for MCL after prior covalent BTK inhibitor exposure. Rule chairs the UK Lymphoma Group MCL working group and has published extensively on MCL biology, the MCL International Prognostic Index (MIPI), and blastoid variant MCL management.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Acalabrutinib in Relapsed/Refractory MCL
Served as global principal investigator for ACE-LY-004, the pivotal phase II trial leading to accelerated FDA approval of acalabrutinib in r/r MCL. The trial demonstrated high overall response rates with a favorable safety profile compared to ibrutinib.
Pirtobrutinib in BTKi-Pretreated MCL
Contributed to BRUIN trial data establishing pirtobrutinib as the first non-covalent (reversible) BTK inhibitor with meaningful activity in patients with MCL who had progressed on prior covalent BTK inhibitors, addressing a major unmet need.
MCL Prognostic Index and Risk Stratification
Co-developed the mantle cell lymphoma International Prognostic Index (MIPI) and its biological extension (MIPIb), which incorporate Ki-67 proliferation index into risk stratification and are now used in virtually all MCL clinical trials worldwide.
Representative Works 代表性著作
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
The Lancet (2018)
Pivotal trial establishing acalabrutinib as an effective and well-tolerated BTK inhibitor option in relapsed MCL.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
The Lancet (2022)
First demonstration of clinical efficacy of a non-covalent BTK inhibitor in covalent BTKi-pretreated MCL patients.
The Mantle Cell Lymphoma International Prognostic Index: a retrospective analysis of patients treated in European MCL Network trials
Journal of Clinical Oncology (2008)
Landmark paper introducing and validating the MIPI score, now standard for MCL risk stratification globally.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-20 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 西蒙·鲁尔 的研究动态
Follow Simon Rule's research updates
留下邮箱，当我们发布与 Simon Rule（Plymouth Hospitals NHS Trust / University of Plymouth）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment